Ad
related to: is simvastatin bad for kidney disease list of names for women
Search results
Results from the WOW.Com Content Network
Simvastatin, sold under the brand name Zocor among others, is a statin, a type of lipid-lowering medication. [4] It is used along with exercise, diet, and weight loss to decrease elevated lipid levels. [4] It is also used to decrease the risk of heart problems in those at high risk. [4] It is taken by mouth. [4]
There is some evidence that appropriate use of statin medications in people with chronic kidney disease who do not require dialysis may reduce mortality and the incidence of major cardiac events by up to 20% and are not that likely to increase the risk of stroke or kidney failure. [16] Asthma
An ingredient in "A.P.C." tablet; withdrawn because of risk of cancer and kidney disease [42] Germany Denmark, UK, US, others Reason: nephropathy. [3] Phenformin and Buformin: 1977 France, Germany US Severe lactic acidosis [3] Phenolphthalein: 1997 US Possible carcinogen. [43] Phenoxypropazine: 1966 UK Hepatotoxicity, drug intereaction. [3 ...
Creutzfeldt–Jakob disease: CKD Chronic kidney disease: CLOVES syndrome Congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and skeletal/spinal abnormalities syndrome CML Chronic myelogenous leukemia: CMs Chiari malformations: CMT disease Charcot–Marie–Tooth disease: CMT1A Charcot–Marie–Tooth disease type 1A CMT1B
Nephrotoxicity is toxicity in the kidneys. It is a poisonous effect of some substances, both toxic chemicals and medications, on kidney function. [1] There are various forms, [2] and some drugs may affect kidney function in more than one way. Nephrotoxins are substances displaying nephrotoxicity.
Sitagliptin is a dipeptidyl peptidase-4 inhibitor and simvastatin is an HMG-CoA reductase inhibitor. [1] These two disorders commonly occur in people at the same time, and have been typically treated with administration of these medications separately. The combination was approved in 2011, and sold under the brand name Juvisync by Merck ...
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
Chronic kidney disease. ACEis or ARBs should be included in the treatment plan to improve kidney outcomes regardless of race or diabetic status. [7] [16] Late-stage dementia should consider deprescribing antihypertensives, according to the Medication Appropriateness Tool for Comorbid Health Conditions in Dementia (MATCH-D). [63] Diabetes mellitus.
Ad
related to: is simvastatin bad for kidney disease list of names for women